Identifying Meibomian Gland Dysfunction Biomarkers in a Cohort of Patients Affected by DM Type II.
Alessandro AbboudaAntonio FloridoFilippo AvogaroJohn BladenEnzo Maria VingoloPublished in: Vision (Basel, Switzerland) (2023)
(1) Background: Meibomian gland dysfunction (MGD) among patients with diabetes mellitus (DM) is a common manifestation of dry eye syndrome (DES). (2) Methods: The purpose of this study is to identify clinical parameters and biomarkers useful to improve the follow-up and the treatment of these patients. We have used an ocular surface disease index (OSDI) questionnaire, Schirmer test I/II, tear film break-up time (TF-BUT), fluorescein plus lissamine green staining, Marx's line (ML), and meibomian gland (MGs) morphology using Sirius ® Topographer (CSO, Costruzione Strumenti Oftalmici, Florence, Italy). Blood sample analysis included glucose, glycated hemoglobin, lipid profile, cortisol, dehydroepiandrosterone sulfate (DHEA-S), androstenedione (ASD) and testosterone. (3) Results: Cortisol and ASD were positively correlated with an increase of MG tortuosity, and an Increased level of triglycerides was associated with a reduction of MGs length. DHEAS levels lowered with age and were associated with ocular surface staining. (4) Conclusions: Future studies, perhaps including meibum lipid analysis and tear cytokine levels, may also further elucidate the connection between these parameters, MG architecture and function.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- autism spectrum disorder
- prognostic factors
- oxidative stress
- attention deficit hyperactivity disorder
- patient reported outcomes
- intellectual disability
- glycemic control
- metabolic syndrome
- insulin resistance
- case report
- blood glucose
- red blood cell
- blood pressure
- combination therapy
- psychometric properties
- room temperature
- data analysis